Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Conference Call February 7, 2024 4:30 PM ET

Company Participants

Jennifer Viera - IR

Jay Luly - President and CEO

Paul Mellett - CFO

Scott Rottinghaus - Chief Medical Officer

Tara Kieffer - Chief Product Strategy Officer

Conference Call Participants

Roy Buchanan - JMP

Roanna Ruiz - Leerink

Amy Li - Jefferies

Eric Joseph - JPMorgan

Operator

Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal First Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode. There will be a question-and-answer session at the end of the prepared remarks. Please be advised that this call is being recorded.

I would now like to turn the call over to Jennifer Viera, Investor Relations. Please go ahead.

Jennifer Viera

Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal first quarter financial results, was issued this afternoon and is available on our website.

Making remarks on today's call are Dr. Jay Luly, President and Chief Executive Officer; and Paul Mellett, our Chief Financial Officer. Dr. Scott Rottinghaus, our Chief Medical Officer; and Dr. Tara Kieffer, our Chief Product Strategy Officer, will be available during the Q&A portion of this call.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that, could cause our actual developments and results to differ materially from those statements.

A description of these risks is in our most recent Form 10-K, and our other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call.

With that, I'd like to turn the call over to Dr. Jay Luly, President and CEO. Jay?

Jay Luly

Thank you, Jennifer, and good afternoon, everyone.

In the first quarter of 2024, Enanta began an important year, which has the potential to advance our programs, in both virology and immunology and drive value across the company. Through our recent expansion into immunology, our mission continues to center around the development of small molecule treatments for indications of high unmet need, and we are leveraging our drug discovery capabilities, to bolster our pipeline for near and long-term value creation.